|本期目录/Table of Contents|

[1]余荣祥,梁栋.特发性肺纤维化的诊疗进展[J].慢性病学杂志,2019,20(04):523-525.
点击复制

特发性肺纤维化的诊疗进展(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
20
期数:
2019年04期
页码:
523-525
栏目:
综 述
出版日期:
2019-05-16

文章信息/Info

Title:
-
作者:
余荣祥; 梁栋
南京市中医院呼吸科，南京 210000
Author(s):
-
关键词:
特发性肺纤维化; 吡非尼酮; 尼达尼布
Keywords:
-
分类号:
R563.9
DOI:
-
摘要:
特发性肺纤维化（IPF）是一种进行性、不可逆、致命的肺部疾病。目前，其发病机制仍不甚清楚，诊断 技术和治疗方法仍在探索与发展。本研究就国际上对IPF发病机制的研究、诊断标准更新和实践情况、治疗药物 前沿研究进展进行论述与总结，同时对现存问题及前景进行了客观描述，以期对国内医务人员的临床工作有所帮助。
Abstract:
-

参考文献/References:


[1] Nogee L, Dunbar AE, Wert S,et al.A mutation in the surfactant protein C gene associated with familial interstitial lung disease [J]. N Engl J Med, 2001,344(8):573-579.
[2] Tanjore H, Cheng DS, Degryse AL,et al. Alveolar epi-thelial cells undergo epithelial- to- mesenchymal transition in response to endoplasmic reticulum stress [J]. J Biol Chem,2011,286(35):30972-30980.
[3] Nathan N, Giraud V, Picard C,et al. Germline SFTPA1mutation in familial idiopathic interstitial pneumonia and lung cancer [J]. Hum Mol Genet, 2016,25(8):1457-1467.
[4] Wang Y, Kuan PJ, Xing C,et al. Genetic defects in sur-factant protein A2 are associated with pulmonary fibrosis and lung cancer [J]. Am J Hum Genet, 2009,84(1):52-59.
[5] Crossno PF, Polosukhin VV, Blackwell TS,et al. Identi-fication of early interstitial lung disease in an individual with genetic variations in ABCA3 and SFTPC [J]. Chest, 2010,137(4):969-973.
[6] Stanley SE, Gable DL, Wagner CL,et al. Loss-of-func-tion mutations in the RNA biogenesis factor NAF1 predis-pose to pulmonary fibrosis- emphysema [J]. Sci Transl Med,2016,8(351):ra107-351.
[7] Armanios M. Telomerase and idiopathic pulmonary fibrosis [J]. Mutat Res, 2012,730(1-2):52-58.
[8] Kropski JA, Mitchell DB, Markin C,et al.A novel dys-kerin (DKC1) mutation is associated with familial intersti-tial pneumonia [J]. Chest, 2014,146(1):e1-7.
[9] Alder JK, Stanley SE, Wagner CL,et al. Exome se-quencing identifies mutant TINF2 in a family with pulmo-nary fibrosis [J]. Chest,2015,147(5):1361-1368.
[10] Stuart BD, Choi J, Zaidi S, et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmo-nary fibrosis and telomere shortening [J]. Nat Genet, 2015, 47(5):512-517.
[11] Tummala H, Walne A, Collopy L,et al. Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenital [J]. J Clin Invest, 2015,125(5): 2151-2160.
[12] Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis [J]. N Engl J Med, 2012,364(16):1503-1512.
[13] Taskar VS. Is idiopathic pulmonary fibrosis an environmen-tal disease? [J]. Proc Am Thorac Soc, 2006,3(4):293-298.
[14] Spira A, Beane J, Shah V, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome [J]. Proc Natl Acad Sci, 2004,101(27):10143-10148.
[15] Taskar V, Coultas D. Exposures and idiopathic lung dis-ease [J]. Semin Respir Crit Care Med, 2008,29(6):670-679.
[16] Han MLK, Zhou Y, Murray S,et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study [J]. Lancet. Respir Med, 2014,2(7):548-556.
[17] Huang Y, Ma SF, Espindola MS,et al. Microbes are as-sociated with host innate immune response in idiopathic pulmonary fibrosis [J]. Am J Respir Crit Care Med, 2017, 196(2):208-219.
[18] Raghu G, Collard HR, Egan JJ,et al. An official ATS/ ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence- based guidelines for diagnosis and management [J]. Am J Respir Crit Care Med, 2011,183(6):788-824.
[19] Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease [J]. Eur Respir J,2013,42(3):750-757.
[20] Watadani T, Sakai F, Johkoh T,et al. Interobserver vari-ability in the CT assessment of honeycombing in the lungs [J]. Radiology, 2013,266(3):936-944.
[21] Raghu G, Lynch D, Godwin JD,et al. Diagnosis of idio-pathic pulmonary fibrosis with high-resolution CT in pa-tients with little or no radiological evidence of honeycomb-ing: secondary analysis of a randomised, controlled trial [J]. Lancet Respir Med, 2014,2(4):277-284.
[22] Raghu G, Wells AU, Nicholson AG,etal. Effect of ninte-danib in subgroups of idiopathic pulmonary fibrosis by diag-nostic criteria [J]. Am J Respir Crit Care Med, 2017,195 (1):78-85.
[23] Ryerson CJ, Corte TJ, Lee JS,etal. A Standardized Diag-nostic Ontology for Fibrotic Interstitial Lung Disease: An International Working Group Perspective [J]. Am J Respir Crit Care Med,2017,196(10):1249-1254.
[24] Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis [J]. Am J Respir Crit Care Med,2010,181(8):832-837.
[25] Salisbury ML, Xia M, Murray S,et al. Predictors of idio-pathic pulmonary fibrosis in absence of radiologic honey-combing: a cross sectional analysis in ILD patients under-going lung tissue sampling [J]. Respir Med, 2016(118):88-95.
[26] King TE, Bradford WZ, Castro- Bernardini S,et al. A phase 3 trial of Pirfenidone in patients with idiopathic pul-monary fibrosis [J]. N Engl J Med,2014,370(22):2083-2092.
[27] Azuma A, Nukiwa T, Tsuboi E,et al. Double- blind, placebo-controlled trial of pirfenidone in patients with idio-pathic pulmonary fibrosis [J]. Am J Respir Crit Care Med, 2005,171(9):1040-1047.
[28] Taniguchi H, Ebina M, Kondoh Y,etal. Pirfenidone in id-iopathic pulmonary fibrosis [J]. Eur Respir J, 2010,35(4): 821-829.
[29] Noble PW, Albera C, Bradford WZ,et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials [J]. Lancet, 2011,377(9779):1760-1769.
[30] Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP: an open-label ex-tension study of pirfenidone in patients with idiopathic pul-monary fibrosis [J]. Sarcoidosis Vasc Diffus Lung Dis, 2014,31(3):198-205.
[31] Richeldi L, Costabel U, Selman M,et al. Efficacy of a tyrosine Kinase inhibitor in idiopathic pulmonary fibrosis[J]. N Engl J Med, 2011,365(12):1079-1087.
[32] Bonella F, Kreuter M, Hagmeyer L,et al. Insights from the German compassionate use program of Nintedanib for the treatment of idiopathic pulmonary fibrosis [J]. Respira-tion, 2016,92(2):98-106.
[33] Sampson C, Gill BH, Harrison NK,et al. The care needs of patients with idiopathic pulmonary fibrosis and their car-ers (CaNoPy): results of a qualitative study [J]. BMC Pulm Med,2015(15):155.
[34] Lindell KO, Liang Z, Hoffman LA,et al. Palliative care and location of death in decedents with idiopathic pulmo-nary fibrosis [J]. Chest,2015,147(2):423-429.
[35] Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial [J]. Ann Intern Med, 2012,157(6):398-406.
[36] Lindell KO, Olshansky E, Song MK,et al. Impact of a disease- management program on symptom burden and health-related quality of life in patients with idiopathic pul-monary fibrosis and their care partners [J]. Hear Lung J Acute Crit Care,2010, 39(4):304-313.
[37] Gomes-Neto M, Silva CM, Ezequiel D,et al. Impact of Pulmonary Rehabilitation on Exercise Tolerance and Quali-ty of Life in Patients With Idiopathic Pulmonary Fibrosis: A SYSTEMATIC REVIEW AND META- ANALYSIS [J]. J Cardiopulm Rehabili Prev, 2018,38(5):273-278.
[38] Jones MG, Fabre A, Schneider P, et al. Three-dimen-sional characterization of fibroblast foci in idiopathic pulmo-nary fibrosis [J]. JCI Insight [Internet],2016:1.
[39] Maher TM, Oballa E, Simpson JK,et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study [J]. Lancet Respir Med,2017,5(12):946-955.

备注/Memo

备注/Memo:
作者简介：余荣祥，硕士，住院医师，研究方向：呼吸系 统疾病 通信作者：梁栋，E-mail：1057560504@qq.com
更新日期/Last Update: 2019-04-28